Predicting Individual Prognosis and Treatment Response in Lung Cancer
Lung cancer is the most commonly diagnosed cancer worldwide, with approximately 1.6 million new cases diagnosed each year. Non-small-cell lung cancer (NSCLC), which accounts for more than 85% of all lung cancer cases, has a five-year survival rate of about 15% and is the leading cause of cancer death in the US. Each stage in NSCLC progression is associated with multiple treatment options, and physicians choose among these options on the basis of past experience and intuition. New treatments for NSCLC are increasingly being introduced into standard of care, further complicating the decisions concerning the best therapeutic avenue for each individual patient. LC PrediCare is a rational decision support tool that can take the guesswork out of these decisions. It uses an NSCLC patient's individual clinical data, in combination with sophisticated mathematical modeling technology, to predict the patient's disease progression and response to different treatment regimens. At any stage during the treatment period, the physician can enter the patient's current clinical data (genetic mutations, histology and biochemistry profiles, response to prior therapies, etc.) into the tool and receive recommendations regarding the most effective treatment path from that point forward.